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A Structural Basis for LCMV Immune Evasion:
Subversion of H-2Db and H-2Kb Presentation of gp33
Revealed by Comparative Crystal Structure Analyses
by selection of variants with mutated amino acids in the
presented peptides. These mutations result in altered
binding to MHC and/or changing of the peptide interac-
tion with the TCR. Such evasion strategies present a
considerable challenge to the antiviral T cell immune
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response, enabling some viruses such as LCMV, HBV,1Microbiology and Tumor Biology Center
HCV, EBV, influenza, HIV, and SIV to survive and persistKarolinska Institutet
in hosts (Borrow and Shaw, 1998; Lucas et al., 2001).2 Center for Molecular Medicine
Additional strategies include induced resistance to apo-Karolinska Hospital
ptosis in viral-infected cells and increased apoptosis of3 Department of Medical Biochemistry and Biophysics
viral-specific CTL (Xu et al., 2001).Karolinska Institutet
LCMV is a noncytopathic RNA virus that infects cellsS-171 77 Stockholm
of the immune system in the mouse, its natural host,4 Department of Biochemistry
suppressing cellular and humoral immune responsesRoyal School of Technology
and causing persistent infection, possibly leading toS-106 91 Stockholm
chronic immunopathological disease in the host (Zinker-Sweden
nagel et al., 1999). In H-2b mice (e.g., C57BL/6 mice),
the acute phase of LCMV infection is characterized by
a CD8 T cell response in which the majority of the CTLsSummary
are directed against three immunodominant epitopes
(Moskophidis and Zinkernagel, 1995). More than 50%LCMV infection of H-2b mice generates a CD8 CTL
of the total LCMV-specific CTL activity is directed to-response mainly directed toward three immunodomi-
ward one such peptide, gp33, which is immunodominantnant epitopes. One of these, gp33, is presented by
in the context of both H-2Kb and H-2Db (Hudrisier et al.,both H-2Db and H-2Kb MHC class I molecules. The
1997).virus can escape immune recognition in the context
The importance of both MHC class I molecules inof both these MHC class I molecules through single
determining the course of LCMV infection has beenmutations of the peptide. In order to understand the
demonstrated in studies of knockout mice (Perarnau etunderlying structural mechanism, we determined the
al., 1999). Upon CTL selection pressure, escape viruscrystal structures of both complexes. The structures
variants emerge. Some of these are based on one singlereveal that the peptide is presented in two diametri-
amino acid exchange in the immunodominant epitope,cally opposed manners by H-2Db and H-2Kb, with resi-
yet they result in no presentation and/or recognition indues used as anchor positions in one MHC class I
the context of both H-2Kb and H-2Db (Aebischer et al.,molecule interacting with the TCR in the other. Impor-
1991; Pircher et al., 1990; Puglielli et al., 2001; and refer-tantly, the peptide’s N-terminal residue p1K protrudes
ences within). The picture is complex, although somefrom the binding cleft in H-2Kb. We present structural
consistent patterns emerge. In summary, clones dis-evidence that explains the functional consequences
playing single mutations V35 to L35, Y36 to F36, and F38 toof single mutations found in escape variants.
L38 in the LCMV glycoprotein sequence escape gp33-
specific CTL response in the context of both H-2b classIntroduction
I molecules. These mutations correspond to positions
3, 4, and 6 in the gp33 peptide. The interaction between
Viral infection involves a series of complex interactions
gp33 and its escape variants on the one hand and each
between host and infective agent. The host utilizes a of H-2Kb and H-2Db on the other hand has been studied
variety of immunological means to eliminate the virus extensively in binding and functional assays. Escape
and thus minimize associated pathological conse- variants have either been isolated from infected mice
quences, while the virus employs strategies to over- or designed and synthesized. Some of these mutants fail
come such immune mechanisms and persist in the host to bind H-2Kb, H-2Db, or both; others bind the restriction
(Tortorella et al., 2000). The ability to clear infections element well and appear rather to affect TCR recogni-
with noncytopathic viruses, such as lymphocytic chorio- tion, as studied by CTL assays or surface plasmon reso-
meningitis virus (LCMV), is predominantly attributed to nance. The latter category may include peptides that
CD8 cytotoxic T lymphocytes (CTL). Virus-specific are no longer recognized at all, as well as partial agonists
CD8 CTLs recognize viral antigens at the surface of and antagonists (Bachmann et al., 1998; Tissot et al.,
infected cells in the context of major histocompatibility 2000). All the reported in vivo and in vitro data (including
complex (MHC) class I molecules, and the response is analyses of peptide binding, TCR-MHC binding kinetics,
usually directed toward a few immunodominant pep- and functional T cell assays) in the LCMV system sup-
tides. Viruses can counteract CTL responses, for exam- port the hypothesis that mutations in LCMV genes are
ple, by production of proteins that perturb the mecha- critical for deciding the outcome of viral infection.
nisms of antigen processing and peptide transport or The main purpose of this study was to provide a struc-
tural platform to explain how single amino acid mutants
in one epitope can allow the virus to escape CTL-medi-5 Correspondence: adnane.achour@mtc.ki.se
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Table 1. Data Collection and Refinement Statistics
H-2Db/gp33 H-2Kb/gp33
Data Collection
Resolution (A˚) 20.0–2.85 (2.90–2.85) 20.0–2.95 (3.0–2.95)
Space group P21 P21
Number of molecules/asymmetric unit 4 2
Number of reflections
Observed 135,354 46,919
Unique 46,560 20,422
I/ 12.0 (9.8) 8.4 (3.5)
Completeness (%) 92.6 (98.0) 86.8 (62.2)
Rsym (%) 9.6 (25.4) 13.0 (24.2)
Refinement Statistics
Rcryst (%) 24.1 22.9
Rfree (%) 27.9 28.6
Number of atoms
Total 12,660 6,343
Solvent 89 84
Rmsd from ideal geometry
Bond length 0.019 0.018
Bond angles 1.92 1.89
Ramachandran plot (%)
Residues in most favoured regions 87.7 86.6
Residues in additional allowed regions 12.3 13.4
Residues in generously and disallowed regions 0 0
Figures in parentheses correspond to the highest resolution shell.
ated recognition in the context of two different MHC spectively). The final electron density maps are of good
quality (Figure 1) with well-defined polypeptide chains.class I molecules. We have solved the crystal structures
of H-2Db and H-2Kb in complex with the immunodomi- In particular, the electron density for all residues in con-
tact with the peptide is clearly defined. The structure ofnant LCMV-derived gp33 peptide (KAVYNFATM), which
revealed how the same peptide can bind to two different H-2Db/gp33 (KAVYNFATM) is very similar to the struc-
ture of H-2Db/gp33C (KAVYNFATC) (Tissot et al., 2000),MHC class I molecules. We here demonstrate that gp33
binds in two diametrically opposed manners to H-2Db with an overall root mean square deviation of 0.46 for
all of the heavy chain in complex with the peptides andand H-2Kb, with differences throughout the whole length
of the peptide. One novel finding was that the peptide’s 2 microglobulin (2m), and of 0.25 for the residues corre-
sponding to the 1 and 2 domains (residues 1–182).N-terminal residue p1K protrudes from the binding cleft
in H-2Kb. The structures also reveal that the same con- Comparison of these two structures reveals that the side
chain of the p9 residue (i.e., M or C) is not critical forserved single mutations at positions 4 or 6 of the peptide
directly affect MHC (but not TCR) contacts when pre- the conformation of gp33 within the MHC complex. This
has also been confirmed by alanine substitution at thesented by H-2Kb and TCR (but not MHC) contacts when
gp33 is presented by H-2Db. Other mutations, such as same position that did not result in any impairment of
gp33-specific CTL activity (Lewicki et al., 1995).p3V to L, affect MHC contacts in both complexes but
in different binding pockets. The structures allow us to
explain how the same mutation in an immunodominant The Nonameric gp33 Peptide Binds as an Octamer
peptide permits the evasion of this epitope and, ulti- in the H-2Kb Peptide Binding Cleft
mately, of the LCMV virus in the context of both H-2Db Surprisingly, the structure of H-2Kb/gp33 reveals that
and H-2Kb. only eight residues of the nonamer gp33 epitope (resi-
dues p2A to p9M) occupy the peptide binding groove
of H-2Kb, leaving p1K outside the cleft at the N terminus.Results and Discussion
This is in agreement with the known minimal peptide
sequence for optimal H-2Kb-restricted gp33-specificOverall Structures of the H-2Db/gp33
and H-2Kb/gp33 Complexes CTLs (Hudrisier et al., 1997) but in contrast to the vast
majority of peptides known to bind to MHC class I mole-As expected from the high degree of sequence identity,
the overall structures of both H-2Db and H-2Kb in com- cules through a network of hydrogen bond interactions
between the amino and carboxyl termini of the peptideplex with the immunodominant LCMV-derived peptide
gp33 are very similar to previously reported MHC crystal and conserved amino acids in the A- and F-pockets at
the ends of the peptide binding cleft. These interactionsstructures. The Rcryst and Rfree values for the refined mod-
els of H-2Db/gp33 are 24.1% and 27.9%, respectively, determine the fixed orientation of the bound epitopes
with the N terminus in pocket A and the C terminus inand 22.9% and 28.6% for the H-2Kb/gp33 complex, re-
spectively (Table 1). The stereochemistry is as expected pocket F and restricts their length to 8–9 amino acids.
The hydrogen bonds appear to provide a general modefor models at these resolutions (2.85 A˚ and 2.95 A˚, re-
A Structural Basis for Viral Immune Evasion
759
Figure 1. Electron Density Maps for gp33
Annealed omit 2Fo-Fc electron density map of
gp33 when bound to H-2Db (upper panel) and
H-2Kb (lower panel), contoured at 1.0 . The
final models of MHC-peptide complexes are
isplayed for comparison. The peptides are
depicted with their N termini to the left and
their C termini to the right, illustrating the an-
chor positions (underlined and vertical arrows).
The parts of the peptide that protrude above
the surfaces of the complex are indicated
by the thick horizontal arrows on each side
of the peptide. In the lower panel, lysine at
position 1 of the peptide protrudes upward,
although the electron density does not permit
us to assign its orientation without ambiguity.
The distance between the N and C termini of
gp33 in H-2Db and the side chain of p2A at
the N terminus and the C terminus in H-2Kb
is depicted by a scale bar at the bottom of
each image.
of binding for short peptides that is MHC allele and The substitution of peptide residue p1 with p2 in the
H-2Kb/gp33 structure, allowing for extension of p1,peptide sequence independent. The majority of longer
peptides utilize this mode of binding and are accommo- might be expected to affect the structural integrity at the
N-terminal part of the peptide binding cleft. However, adated through bulging out of the peptide binding cleft
or zigzagging within the cleft, although some will pro- comparison of the structure of H-2Kb/gp33 with other
available H-2Kb structures reveals no major changes intrude out of the cleft.
The electron density within the peptide binding cleft the positioning of the side chains surrounding the N-ter-
minal region of the bound peptide (Figure 2). The clusterof H-2Kb is of good quality and clearly corresponds to
the octamer sequence AVYNFATM (Figure 1). The first of residues Y7, Y59, E63, Y159, W167, and Y171 that
interact with the peptide residue at p1 (in other H-2Kbresidue of gp33, p1K, appears very flexible, explaining
why no electron density at an acceptable -threshold structures) and p2 (in H-2Kb/gp33) displays the same
relative geometric organization in each structure, withcould be discerned for the side chain of p1K. We there-
fore did not include this residue in the model or in the only minor differences depending on the properties of
the peptide residue. Thus, there is no overall conse-figures. The structure of the gp33 epitope in complex
with H-2Kb is thus presented with the main chain nitro- quence of departure from a canonical N-terminal pep-
tide bound structure.gen of the alanine residue at position 2 of the peptide
pointing out of the peptide binding cleft toward the sol- The presence of p1K in the structure of the H-2Kb/
gp33 complex was confirmed indirectly. (1) The samevent. The peptide gp33–43 (KAVYNFATCGI) was found
to be the optimal binder to H-2Kb (Hudrisier et al., 1997). batch of nonameric gp33 peptide was used for the re-
folding of both H-2Kb and H-2Db. (2) Mass spectrophoto-Furthermore the nonameric (gp33–41) and octameric
(gp34–41) sequences bound equally well to H-2Kb, al- metric and chromatographic analyses of the gp33 pep-
tide batch did not reveal any octameric contaminantthough at a slightly lower level than the longer gp33–43.
Here we demonstrate that the nonamer KAVYNFATM (data not included). (3) Two sets of data have been re-
trieved from two different crystals of the H-2Kb/gp33binds and occupies the groove of H-2Kb using eight
amino acids. complex. These crystals were produced independently
Immunity
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Figure 2. The Protrusion of p1K in the H-2Kb/
gp33 Structure Does Not Affect the Overall
Conformation of the N-Terminal Part of the
Peptide Binding Cleft
Conformation of side chain residues inter-
acting with the N termini of peptides in the
crystal structures of H-2Kb/gp33 (orange),
H-2Kb/OVA (PDB 1VAC, cyan), H-2Kb/DEV8
(PDB 1LEG, violet), and H-2Kb/SEV (PDB
2VAB, blue) after superposition of the 12
domains. Note that the p2A residue in the
gp33 peptide occupies the position corre-
sponding to the p1 residue normally present
in other crystal structures of H-2Kb. The orien-
tation of the peptides is depicted by a black
arrow (from the N terminus toward the C ter-
minus). The overall geometric organization is
similar in all the depicted structures.
from each other, but both structures revealed the pres- tionally, functional and peptide elution studies have also
confirmed that despite the importance of the N andence of the p2-p9 peptide section inside the H-2Kb cleft
and of a very flexible lysine side chain that protrudes C termini for the binding of peptides to MHC class I
molecules (Bouvier and Wiley, 1994), these can emergeout toward the solvent.
The extension of the p1K side chain at the N terminus at both ends of the MHC class I binding groove. Addition
of two amino acids at the N or C termini of the VSV8of the H-2Kb peptide binding cleft supports previous
functional and structural studies that have demon- and OVA9 peptides still permitted binding to H-2Kb (Mat-
sumura et al., 1992). In the same way, peptides extendedstrated that the termini of an epitope are not absolutely
required for binding to the MHC class I groove. The at their N termini have been demonstrated to still bind
to H-2Kd (Fahnestock et al., 1994) while longer epitopesfirst structural evidence that longer peptides have the
capacity to protrude out of the peptide binding cleft was from a large panel of peptides can be accommodated
by protrusion at both ends of the peptide binding cleftsprovided by the crystal structure of HLA-A2 in complex
with a decameric peptide (Collins et al., 1994). This epi- of H-2Kk, H-2Kb, and H-2Db (Stryhn et al., 2000). The
existence of naturally processed peptide ligands lackingtope displayed a binding pattern similar to other MHC
class I binding peptides at the N terminus and through- the amino-terminal group but still able to form a complex
with classical MHC class I molecules in vivo has alsoout the entire length of the peptide, but the last residue
protruded out of the binding cleft at the C terminus. The been demonstrated (Yague et al., 2001). These natural
MHC class I ligands lacking the amino-terminal groupprotrusion of the peptide is even more pronounced in
the crystal structure of H2-M3, in which the nonameric were identified in endogenous peptide pools isolated
from HLA-B39 allotypes together with their N-terminallyformylated peptide extends out of the groove with the
last three residues (Wang et al., 1995). More recently, extended canonical counterparts. The same study dem-
onstrated that peptides lacking the amino-terminalcrystal structures of HLA-A2 in complex with terminally
modified synthetic peptides, with either the amino or group bind HLA-B39 in vitro similarly to their N-ter-
minally extended counterparts. The structure of thethe carboxy-terminal groups substituted by a methyl
group, were successfully determined (Bouvier et al., LCMV-derived peptide gp33 in complex with H-2Kb ex-
tends these previous structural and functional studies1998). The peptide modified at the N terminus bound to
HLA-A2 in a manner similar to the wild-type peptide by demonstrating the protrusion of the peptide ligand
at the N terminus end of the MHC class I groove.except for the N terminus where the methyl group
pointed up and out of the cleft in a very similar way to
the structure that we present in this work. The LCMV-Derived gp33 Is Presented in Diametrically
Opposite Conformations by H-2Db and H-2KbAll of the structural studies described above demon-
strate that although the N and C termini play major roles While both H-2Db and H-2Kb bind gp33, they do so in
completely different ways due to the requirements im-in the binding of the epitopes, they are not always re-
quired. Shorter peptides can still bind through a network posed by the peptide binding clefts of the respective
MHC class I molecules. The peptide has the characteris-of water molecules, and longer peptides will protrude
from the ends of the binding cleft in some cases. Addi- tic conformation for H-2Db, in which it bulges from resi-
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Figure 3. The Peptide gp33 Bound to the
Clefts of the MHC Class I H-2Db and H-2Kb
Molecules
The peptide is represented as a stick model,
while the MHC class I molecules are repre-
sented by their surfaces (viewed from above).
The image was created using the Grasp pro-
gram (Nicholls et al., 1991). The pockets per-
mitting binding of different sections of the
peptide are displayed. The positions of (A)
H-2Db and (B) H-2Kb residues important for
the binding of gp33 and a few other residues
are indicated. Negatively charged regions of
the surface are given in red and positively
charged regions in blue with a scale from15
kT to 15 kT. Peptide residue labels begin
with p.
dues 6 to 8 (Young et al., 1994), with p1K, p7A, and chors (p3V and p4Y) (Figures 3 and 4). This contrasts
with the only previous structural studies of how oneparticularly p4Y and p6F projecting up into the solvent
(Figures 3A and 4). By contrast, in H-2Kb the peptide peptide can bind two different MHC class I molecules,
based on the Sendai virus nucleoprotein-derived pep-binds deeply in the cleft and has a flatter conformation
(Figures 3B and 4) with three residues available for inter- tide NP324-332 (FAPGNYPAL) binding to H-2Kb (Fre-
mont et al., 1992) and H-2Db (Glithero et al., 1999). Theaction with the TCR (p1K, p5N, and p8T). Note that p4Y
and p6F, which act as TCR contact residues when the Sendai virus-derived peptide was positioned in the
groove in a similar manner for the two MHC class Ipeptide is presented by H-2Db, are utilized as deeply
buried anchor residues when gp33 is presented by H-2Kb molecules in the N and C termini (positions 1–3 and 8–9,
respectively), i.e., with no shift, although the pattern(Figures 3 and 4). Comparison of these different confor-
mations reveals a relative shift in the positions of the formed by the residues in the central portion (positions
4–7) differed substantially. To our knowledge, the struc-peptide amino acids in each structure (Figure 4). This
in turn leads to the use of different amino acid side tures presented in our study are the first examples of
the same epitope being presented in two diametricallychains as anchors in different pockets of the two MHC
complexes. Thus, gp33 binds H-2Db with p5N and p9M opposite ways by two different MHC class I molecules.
Our results also verify previous predictions of structuralas main and p3V as a secondary anchors, whereas H-2Kb
uses two main (p6F and p9M) and two secondary an- changes in the central core of the peptide when bound
Immunity
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Figure 4. The gp33 Peptide Is Presented in
Two Diametrically Opposed Manners by H-2Kb
and H-2Db
Superimposed side views of the peptide gp33
depicting the frameshift and the two different
conformations of the bound peptide in H-2Db
and H-2Kb (compare the orientations of p4Y
and p6F). The peptides are depicted with their
N termini to the left and their C termini to
the right. The peptide presented by H-2Db is
colored in yellow while the same sequence
is colored in blue when presented by H-2Kb.
The residues of gp33 when bound to H-2Kb
are underlined.
to these two different MHC class I complexes (Hudrisier bond with N70. A mutation of p4Y to a phenylalanine,
as in escape variants, would abrogate the hydrogenet al., 1997).
bonding to the residues on the 2-helix and significantly
reduce the number of hydrogen bonds between gp33The Structures of H-2Db And H-2Kb in Complex
and H-2Kb (Table 2), resulting in a reduced binding affin-with gp33 Reveal the Molecular Mechanisms
ity of the peptide to H-2Kb. This would probably resultUnderlying LCMV Virus Evasion
in: (1) an altered configuration of the side chains of E152of CD8 CTL Recognition
and, more importantly, of R155, a different set of con-There are at least three mutations in gp33 that lead to
tacts with the TCR; (2) a readaptation of the positioningviral escape in the context of both H-2Db and H-2Kb
of the introduced phenylalanine side chain inside therestriction elements: p3V to L, p4Y to F, and p6F to L.
D-pocket, most probably altering the positioning of theThese mutations are conservative but still permit these
adjacent p5N; and (3) potentially an overall movementMHC-peptide complexes and ultimately the virus to effi-
of this section of the 2-helix, similar to that describedciently evade recognition by specific CD8 T cells. Anal-
previously for index and escape variant structures (Reid
ysis of the structures of gp33 bound to both class I
et al., 1996).
molecules suggests a structural basis for these escape
The side chain of p3V points toward the negatively
mechanisms. This is described in detail below, first with
charged B-pocket of H-2Kb composed of residues Y7,
respect to H-2Kb, then to H-2Db. In principle, the muta-
V9, E24, Y45, and N70 (Figures 3B and 5C). Residues
tions at p4 and p6 directly affect MHC (but not TCR)
E63 and K66 are situated above this pocket (Figure 3B),
contacts when presented by H-2Kb, and TCR (but not K66 being involved in hydrogen bond interactions with
MHC) contacts when gp33 is presented by H-2Db (Figure the backbone carbonyl of p3V. The H-2Kb/gp33 structure
4). The p3V to L mutation affects MHC contacts in both demonstrates that unlike a smaller valine, a leucine can-
H-2Db and H-2Kb but in different pockets (Figure 3). In not be positioned in the B-pocket without either a direct
both H-2Kb and H-2Db, the p3V to L mutation will not effect on the surrounding MHC residues or an impact
affect the binding capacity of gp33 (Moskophidis and on the conformation of gp33 in the peptide binding cleft.
Zinkernagel, 1995), but the structures suggest that it This implies that in order to fit a leucine in the B-pocket,
affects the positioning of p4Y and will thus indirectly the peptide would have to introduce minor rearrangements
impair TCR recognition. which would nevertheless have an impact on: (1) the
In H-2Kb, the phenylalanine residue at position 6 of positioning of p4Y and its capacity to form hydrogen
gp33 (p6F) projects down into the C-pocket, composed bonds with E152 and R155 as described in Figure 5B;
of residues V9, F74, V97, S99, Q114, and Y116 (Figure (2) the positioning of p5N, a major component of the
5A and Table 2). A change from F to L at this position, interaction of the H-2Db/gp33 complex with the TCR;
as observed in escape variants, would result in a shorter and (3) the positioning of the MHC residue K66 which
and less bulky residue. The introduced leucine would not covers the B-pocket and also interacts with the TCR. It
fit the hydrophobic C-pocket as well as a phenylanine, is noteworthy that the pV3L variant stabilized H-2Db and
weakening the binding of the peptide. This may also H-2Kb molecules on the surface of RMA-S cells to a
indirectly affect the conformation of the adjacent p5N, similar extent as the corresponding wild-type gp33 pep-
which has been demonstrated to be the residue of im- tide but induced significantly less specific cytotoxicity
portance for the TCR readout in H-2Kb/gp33 (Hudrisier (Moskophidis and Zinkernagel, 1995).
et al., 1997). As for the H-2Db molecule, both residues p4Y and p6F
Tyrosine at position 4 (p4Y) in gp33 projects down project out of the peptide binding cleft (Figure 4). The
into the D-pocket of H-2Kb formed by residues Q114, escape mutants pF6L (Figure 5D) and pY4F (Figure 5E)
E152, R155, L156, and Y159, where it is involved in the can thus be explained by impaired TCR recognition
formation of three hydrogen bonds with the side chains rather than by impaired MHC binding. Indeed, a mutation
of E152 and R155 (Figure 5B). The side chain of p4Y is of residue p4Y to F impaired the affinity of the p14 TCR
further stabilized by ring stacking with the side chains by 100-fold (Tissot et al., 2000). X-ray crystallographic
structures of TCR/peptide/MHC complexes suggestof Y159 and p6F, while the main chain forms a hydrogen
A Structural Basis for Viral Immune Evasion
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that the entire range of TCR-initiated signals, from ago- concurs with previous results, in which the p3V to L
nism to antagonism, is due to minor rearrangements of mutation resulted in a 50-fold loss of affinity of H-2Db
the TCR CDR loops to accommodate the differences in for the p14 TCR (Moskophidis and Zinkernagel, 1995;
the peptide sequences (Degano et al., 2000; Ding et al., Tissot et al., 2000).
1999; Rudolph and Wilson, 2002). This is illustrated by Finally, the crystallographic structure of H-2Db in com-
our model of the p14 TCR in complex with H-2Db/gp33, plex with gp33 supports the interesting hypothesis that
based on the crystal structure of the 2C TCR in complex the number of LCMV peptides that may be presented
with H-2Kb (Garcia et al., 1996). In this model, p4Y and by MHC class I molecules is limited (Hudrisier et al.,
p6F are located at the interface between the TCR and 1996). The impact of nonanchor residues in the peptide-
H-2Db (Figures 5D and 5E). More precisely, p4Y pro- MHC interaction was investigated and, despite the pres-
trudes directly into the most sensitive part of the TCR, ence of the H-2Db binding motif, the majority of LCMV-
the so-called functional hot spot (Degano et al., 2000) derived peptides displayed very weak or no affinity to
located between the CDR3 domains of the V and V this MHC class I molecule. The sequential comparison
chains (Figure 5E), while the side chain of p6F interacts of 34 such peptides suggested that the presence of a
with the V subunit of the TCR. The pY4F mutation negatively charged residues such as E or D at position
results in an alteration of its capacity to create hydrogen 2 or 3 of the peptide impaired its binding capacity to
bond interactions with: (1) TCR residues Y36 on V, H-2Db. In the crystal structure of H-2Db/gp33, the side
G102 on V, and the MHC residue H155 (Figure 5E), (2) chain of p2A is directed toward the acidic B-pocket
the reduction of the size of this side chain, and finally, formed by residues Y7, E9, S24, and Y45 (Figure 3A)
(3) a more hydrophobic character to this position. while p3V occupies the C-pocket as described above
Besides the loss of hydrogen bonds with both TCR (Figure 5F). Neither of these two pockets could accom-
subunits, the reduction in size of the p4 residue creates modate the size and the negative charges of the glu-
a cavity in the TCR/peptide/MHC interface. Similar cavi- tamic and aspartic acid side chains, explaining why such
ties have been described in the crystal structures of four residues at either of these two positions in LCMV-
different complexes of A6 TCR with HLA-A2 presenting derived peptides would most probably prevent binding
agonistic and antagonistic peptides (Ding et al., 1998, to H-2Db.
1999; Garboczi et al., 1996). These structures were re- Very recently, using an HCV model in chimpanzees,
markably similar even though the MHC/TCR contact Erickson et al. demonstrated that amino acid substitu-
resulted in very different T cell signals. The antagonist tions in class I MHC-restricted epitopes are selected
peptide displayed no structural changes relative to the and possibly maintained by HCV-specific CD8 CTL
wild-type peptide except for a mutation from P to A at populations (Erickson et al., 2001). Most importantly,
position 6. This mutation results in the creation of a the outcome of such an infection could be predicted by
cavity at the interface between the antagonistic MHC/ the escape mutations present in the dominant epitopes
peptide complex and the TCR (Ding et al., 1999). In targeted by CTLs. The escape mutations accumulated
a follow-up study, the T cell antagonist peptide was gradually and seemed to reflect CTL selection pressure
converted into an agonist by stepwise repair of the de- focused on a narrow set of the most dominant epitopes
fect in the TCR/MHC interface using N-alkylated amino at any given point in time. Almost all escape mutations
acids that progressively filled up the cavity, restoring detected in chronically infected animals appeared early
TCR binding affinity and resulting in agonistic signal- in the infection. The structures of H-2Db and H-2Kb in
ing (Baker et al., 2000). Viruses such as LCMV can make complex with the LCMV-derived immunodominant epi-
use of subtle modifications such as the removal of the tope gp33 help us to understand the structural bases
hydroxyl group from the tyrosine side chain to avoid for the escape of LCMV from gp33-specific CD8T cells,
recognition by CD8 T cells. As described above, the ultimately resulting in persistence of the viral infection.
structure of H-2Db in complex with gp33 suggests that
This knowledge might help in creating novel multiepi-
the pF6L mutation may modify the mode of recognition
tope vaccines in which the known immunodominant and
of the H-2Db/gp33 complex by the p14 TCR. This rather
the defined escape mutant peptide sequences are com-conserved substitution would result in the formation of
bined (O’Connor et al., 2001). A panel of such strain-a cavity, which would also influence the affinity of the
specific, tailor-made antiviral vaccines may thus provideTCR to H-2Db and facilitate CDR3 movements, resulting
an improved future therapeutic strategy.in an antagonistic effect (Figure 5D). This concords with
previous studies in which gp33 mutated at the same
Concluding Remarksposition from F to A has been defined as a partial antago-
Combined study of the interaction of LCMV peptidesnist for the p14 TCR (Bachmann et al., 1998).
and H-2b MHC class I molecules by in vitro functionalThe side chain of p3V projects down into the C-pocket
CTL assays and measurement of peptide binding affini-of H-2Db formed by residues Q97, S99, L114, H155,
ties has led to development of molecular theories toY156, and Y159 (Figures 3A and 5F). A mutation from V
explain viral escape through selected amino acid substi-to L at this position would result in sterical hindrance,
tution. The next level of knowledge is gained by solvingaffecting the peptide conformation. It should be noted
crystal structures of the peptide-MHC complexes, en-that the V to L mutation at this position did not markedly
abling all previous analyses to be reassessed in a three-affect the binding of gp33 to H-2Db, while a mutation of
dimensional context. Our novel approach of comparingV to A reduced binding of the peptide to H-2Db (Puglielli
the structures of two MHC class I/peptide complexeset al., 2001). As for H-2Kb, we propose that conforma-
yielded information that only a single MHC class I struc-tional changes of the peptide will affect the positioning
of p4Y and p6F and their interaction with the TCR. This ture could not provide, thus making an important contri-
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Figure 5. Single Substitutions in Escape Mutants Affect the Structural Conformation of Both the H-2Kb/gp33 and H-2Db/gp33 Complexes
In the following figures the peptide binding groove is viewed in different orientations, with the peptide represented as a red line, the differential
occupancy of peptide positions indicated by superimposed images of the amino acids from wild-type (colored in lime-green) or escape mutant
substitutions (colored in orange). The TCR is colored in brown/yellow, and hydrogen bonds appear as dotted lines.
(A) The side chain of p6F projects down in the hydrophobic C-pocket of H-2Kb composed of residues V9, F74, V97, S99, and Y116. The
substitution of p6F for a leucine implies that the side chain would not fill the pocket as well as the former phenylalanine. The 1-helix and
the  sheets are colored in cyan while the 2-helix is rendered transparent (side view).
(B) The side chain of p4Y acts as an important secondary anchor position in the context of H-2Kb. It projects down in the D-pocket where it
forms three hydrogen bonds with the side chains of E152 and R155. A substitution of the tyrosine for a phenylalanine at this position results
in the removal of the hydroxyl group, precluding the possibility of the new side chain maintaining the hydrogen bonds present in the wild-
type peptide (top view).
(C) The side chain of p3V points toward the negatively charged B-pocket of H-2Kb composed of residues E24, Y45, E63, and N70. The relatively
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Table 2. A. Hydrogen Bonds (3.2 A˚) and van der Waals Interactions (3.6 A˚) of the Peptide gp33 with Residues of the Cleft in the H-2Db
Complexa
Hydrogen Bonding
Peptide Residue Atom Atom H-2Db Residue van der Waals Contacts
p1K O OH Y159 M5, Y7, R62, E63, K66,
N OH Y171 W167
NZ OE2 E163
p2A N OE1 E63 Y7, Y45, Y159
O NZ K66
p3V O NE2 Q70 E9, Q70, S99
N OH Y159
p4Y O NE2 H155 K66, Q70
p5N N OE1 Q70 W73, F116, H155, Y156
OD1 NE2 Q97
p6F O NE1 W73 S150, A152, H155
N OH Y156
p7A O NE1 W73 S150
O NE1 W147
p8T O NE1 W147 W73, V76, S77, N80
OG1 NZ K146
p9M OXT ND2 N80 W73, L81, L95, F116, Y123,
OXT NZ K146 W147
O OH Y84
O OG1 T143
N OG S77
B. Hydrogen Bonds (3.2 A˚) and van der Waals Interactions (3.6 A˚) of the Peptide gp33 with Residues of the Cleft in the H-2Kb
Complexa
Hydrogen Bonding
Peptide Residue Atom Atom H-2Kb Residue van der Waals Contacts
p2A O OH Y159 Y7, Y59, K66, T163, W167, Y171
p3V O NZ K66 Y7, E24, Y45, E63, K66
p4Y O ND2 N70 Y159
OH OE2 E152 Q114, L156, Y159
OH NE R155
P5N O NH2 R155 K66
p6F N OD1 N70 V9, S73, F74, V97, S99, Q114, Y116
p7A S73, D77, W147, E152, R155
p8T O NE1 W147 S73, D77
p9M N OD1 D77 F74, T80, L81, Y84, I95,
O OH Y84 Y116, T143
OXT OH Y84
OXT OG1 T143
a The analysis was performed with the contact module contained within the CNS suite of programs (Bru¨nger et al., 1998).
bution to the understanding of viral escape mechanisms. pying the cleft in H-2Kb, while nine are used in H-2Db.
This results in strikingly different peptide conformationsWe first demonstrate how the same immunodominant
viral peptide can bind to two different peptide binding in H-2Db and H-2Kb, e.g., p4Y and p6F act as TCR contact
residues in H-2Db but as buried anchor residues in H-2Kb.clefts using different features, e.g., eight residues occu-
small size of this hydrophobic residue permits it to adapt to the constraints of this pocket. Mutation of this residue to a leucine increases the
size of the side chain, making it difficult for the side chain to adapt to the sterical and charge constraints of the B-pocket. The 1-helix is
rendered transparent while the rest of the heavy chain is colored in cyan (top view).
(D) The side chain of p6F protrudes out of the cleft and acts as a link between the MHC heavy chain and the V domain of the p14 T cell
receptor. In this case p6F contacts a hydrophobic portion of the CDR3 loop of the V domain composed by an alanine at position 101 and
two glycines at positions 102 and 103 (colored in yellow). The substitution of p6F for a leucine would result in an important size reduction of
the side chain, allowing a higher freedom of movement to CDR3-V, which also interacts with the TCR contact residue p4Y (front view).
(E) The side chain of p4Y protrudes out of the H-2Db cleft, positioning itself perfectly in the hot spot of the p14 TCR composed of the CDR3
loops from both V and V. It forms three hydrogen bonds, two of them directly with V (G102) and to the V (Y36) domains of the TCR. The
last hydrogen bond is created with the side chain of a histidine at position 155, linking this domain of the heavy chain to the TCR. The
substitution of the tyrosine present at position 4 of the peptide for a phenylalanine would remove the hydroxyl group, abolishing all the
hydrogen bonds established between H-2Db/gp33 and the p14 TCR (side view).
(F) The side chain of p3V projects down into the C-pocket of H-2Db, formed by residues L114, H155, Y156, Y159, and L160. The substitution
of this side chain for a larger leucine would result in sterical hindrance, implying the rearrangement of the positioning of this residue and
having an impact on the positioning of the adjacent p4Y (front view).
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In the case of H-2Db/gp33, the H-2Db-crystal structure, PDB codeAnother important finding is that p1K protrudes out of
1HOC, with the peptide omitted, was used as a search model. Athe peptide binding cleft in H-2Kb, although the overall
Matthews coefficient calculation suggested the presence of fourconformation of the N-terminal part of the groove is
MHC complexes in the asymmetric unit. The translation search for
unchanged. The structures also suggest how subtle one molecule resulted in one solution with a correlation coefficient
changes with conserved mutations within different resi- of 0.265. This solution was fixed and new rounds of calculations
resulted in a second solution with a correlation coefficient of 0.311.dues of gp33 allow LCMV to escape immune recognition
These two solutions were then fixed, and the same process wasmediated by both MHC molecules through alteration of
used to subsequently find solutions 3 and 4, with a final correlationeither MHC or TCR contact residues.
coefficient of 0.423. The same procedure was used with the struc-Several antigenic ligands exist for any given virus, and
ture of H-2Kb (PDB 1OSZ, as a search model) to find the two solutions
each one is recognized by a subpopulation of CTLs. The for the H-2Kb complex. The final correlation coefficient for the H-2Kb
relative antigen specificities of these CTL subpopula- solutions was 0.547. The refinement of the models was performed
using the CNS suite of programs (Bru¨nger et al., 1998). Four percenttions will differ. Thus, the efficiency of viral antagonists
of the reflections were set aside in both complexes for monitoringin subverting the host’s antiviral immune response and
the refinement by Rfree (Bru¨nger, 1992). Rigid body refinement wasincreasing the chronicity of infection will depend on the
performed, treating the 12 (residues 1–182), 3 (residues 183–relative immunodominance of the epitope being antago-
274), and 2m domains as three separate units. Heavy weighted (wnized. By limiting the number of potentially immunodom- 300), restrained noncrystallographic symmetry was used throughout
inant viral peptides (e.g., LCMV limits to three) and by the initial steps of refinement. The restraints for side chains of sev-
eral residues were released in the late stages of refinement to fitdirecting the host’s immune response toward these epi-
the density. After simulated annealing, the model was rebuilt, wheretopes, LCMV can efficiently secure its escape through
relevant, using the program O (Jones et al., 1991). A clear electronsingle mutations. The emergence of a viral variant dem-
density in the (Fo-Fc) map was observed inside the peptide bindingonstrates that it must have a replicative advantage in
cleft, and the peptide KAVYNFATM could be placed unambiguously
vivo and that as such the variant must alter the balance in both MHC complexes, but for the first residue (p1K) in the H-2Kb
between virus replication and immune control in favor complex. The model was further refined by positional and individual
B factor refinement, resulting in an Rfree drop of about 1%. Eighty-of the virus. Further comparative structural analyses of
nine and eighty-four water molecules were added to the H-2Db andmicrobial peptide-MHC interactions will hopefully serve
H-2Kb complexes, respectively, using the water pick option in CNSto demonstrate whether this exquisite adaptation to life
(3 in the Fo-Fc map). One final round of TLS refinement usingis shared by other pathogens.
Refmac5 (Winn et al., 2001) was performed. In both cases, H-2Db
and H-2Kb, the subunits were considered as different TLS groups.
Experimental Procedures
This resulted in a drop of about 2% in the R/Rfree values of both
models. The final rounds of refinement yielded a final Rfree of 27.9%Preparation of the H-2Db and H-2Kb MHC Complexes
for H-2Db and 28.6 for H-2Kb. It was verified that all water molecules
The peptide gp33 (KAVYNFATM) was purchased from Research
were localized in chemically reasonable positions, at a hydrogen
Genetics (Huntsville, AL). The refolding and the purification of H-2Db
bond distance from any oxygen or nitrogen atom of the protein.
and H-2Kb in complex with the gp33 peptide and the mouse
The stereochemistry of the models was analyzed with PROCHECK
2-microglobulin subunit was conducted as previously described (Laskowski et al., 1993). Solvent accessible surface areas were ana-
(Garboczi et al., 1992).
lyzed within the CNS program package. Refinement statistics are
provided in Table 1.
Crystallization of the H-2Db and H-2Kb MHC Complexes
The best crystals for the H-2Db/gp33 complex were obtained in
Molecular Model of the TCRhanging drops by vapor diffusion in 1.8 M ammonium sulfate, 0.1
The molecular model of the p14 TCR specific for the H-2Db/gp33M Tris Cl (pH 8.5), 3%–4% ethylene glycol at room temperature, or
MHC complex was created using the SWISS-MODEL Protein Model-in 1.6 M ammonium sulfate, 0.1 M Tris Cl (pH 8.0) at 4C. Typically,
ling Server (Guex and Peitsch, 1997). The crystal structure of the4 	l of a 6 mg/ml protein solution in 20 mM Tris Cl (pH 7.0) was
TCR-2C/H-2Kb/DEV-8 peptide complex (PDB code 2CKB) was usedmixed in a 4:3:1 ratio with the crystallization reservoir solution and
as a template for the creation of a preliminary model. This was thenethylene glycol. The drops were allowed to equilibrate at room tem-
superimposed on the structure of H-2Db/gp33/m2m solved in thisperature or at 4C. The best crystals for the H-2Kb complex were
study, and the entire complex was subjected to several energyobtained in 1.85 M NaH2PO4/K2HPO4, 1% MPD or in 18% PEG 8K, minimization rounds using the CNS suite of programs (Bru¨nger et0.1 M Na cacodylate, 0.2 M magnesium acetate, both at room tem-
al., 1998). The quality of the model was continuously assessed usingperature. Typically, 2 	l of a 5 mg/ml protein solution in 20 mM Tris
the PROCHECK program (Laskowski et al., 1993). The coordinatesCl (pH 7.0) were mixed with equal volumes of the crystallization
of the TCR model will be provided upon request.reservoir.
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